The relationship of invasive and non-invasive respiratory therapy to the risk of developing the Retinopathy of Prematurity (ROP)
© Sergeevna et al. 2015
Published: 27 October 2015
ROP occurs in 95% of babies weighting less than 1000 g, all cases that had proceeded to the third stage will cause serious complications or complete blindness . The aim of the study was to evaluate the degree of invasive and noninvasive respiratory therapy affection on the frequency and severity of ROP in the group of risk.
Retrospective analysis of examination of 217 newborn of the risk group. ( In Russian Federation all children under 35 weeks of gestation age or weighting below 2000 gr lie in the group of risk for ROP). Due to the development of Respiratory Distress Syndrome all children needed respiratory therapy on the first week of living. The patients were divided into 3 groups according to the kind of respiratory therapy received. 1st group ( n-=86) received noninvasive respiratory therapy with Nosal Continuous Airway Pressure, 2nd group (n=69) – noninvasive therapy with Biphasic, and 3rd group (n=62) – invasive respiratory therapy with Artificial Respirating Unit.
In 1st group we observed 0 cases of ROP, in 2nd - 3 cases were diagnosed, but all of them had a fast regression afterwards, in 3rd group – 20 children developed ROP, only 15 cases regressed and one child had to go through the laser coagulation of the retina vessels.
Changing from invasive to noninvasive forms of respiratory therapy may lead to significant decrease of the risk of ROP.
- Katargina LA: Prevention, Early diagnosis and Treatment of the Rethinopathy of prematurity. National Guidance. 2013, 1: 794-804. brief editionGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.